PO.CL05.11 · 临床研究
Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 1
- 2625 2625 αTIGIT引导的IL-15模拟物实现强效且安全的抗肿瘤免疫 alphaTIGIT-guided IL-15 mimetics enable potent and safe antitumor immunity Xiangming Liu, Nan Li, Yang-Xin Fu, Zaopeng Yang
- 2626 2626 一种可切割的IL10-TCE对抗TCE诱导的T细胞功能障碍并在无毒性的情况下根除实体瘤 A cleavable IL10-TCE counteracts TCE-induced T cell dysfunction and eradicates solid tumors without toxicity Xinxin Wang, Yang-Xin Fu, Zaopeng Yang
- 2627 2627 ALX006：一款具有同类最佳潜力的PD-1/VEGF双特异性抗体，在临床前模型中展现出卓越的抗肿瘤活性和良好的PK特征 ALX006, a PD-1/VEGF bispecific antibody with best-in-class potential demonstrates superior antitumor activity and favorable PK in preclinical models Zenglin Pei, Yupeng Zhu, Jinglu Xia, Zhaojun An, Barry Duplantis, Yuhao Wang, Yali Wang, Jia Ge, Xiaojin Zhang, Lingjian Yang, Liang Du, Xiangyu He, Yi Li
- 2628 2628 AM109：一款PSMA×CD137双特异性抗体，具有靶点依赖性T细胞激活作用和强效的前列腺癌抗肿瘤活性 AM109, a PSMA×CD137 bispecific antibody with target-dependent T cell activation and potent anti-tumor activity in prostate cancer Dong-Wook Kim, Hyun-Jong Lee, Seong Yeol Kim, Min Yoon, Youngha Lee, In-Sik Hwang, Yoon Lee, Jong-Hoon Kim, Jong-Seo Lee
-
- 2630 2630 MRG008：一款新型EGFR和5T4双特异性抗体-药物偶联物（ADC），在临床前研究中具有强效抗肿瘤活性 MRG008: A novel EGFR and 5T4 bispecific antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies Yuanyuan Yang, Zhijian Cai, Deliang Li, Shoujia Liu, Wenci Gong
-
- 2632 2632 DXP-106：一款具有增强ADCC活性的抗IL1RAP单克隆抗体，展现出体外和体内抗肿瘤效应并已成功完成IND申报支持研究 DXP-106, an anti-IL1RAP monoclonal antibody with enhanced ADCC activity, exhibits both in vitro and in vivo anti-tumor effects and has successfully completed IND-enabling studies Qinghao Liu, Yaqi Ru, Yan Jiang, Huimin Li, Wenbo Li, Lan Yang, Qian Shi
-
-
- 2635 2635 新型肿瘤微环境(TME)激活的白细胞介素-2(IL-2)与抗PD-1或抗PD-1/VEGF-A抗体融合体用于增强抗肿瘤免疫 Novel tumor microenvironment (TME) activated interleukin-2 (IL-2) fused to anti-PD-1 or anti-PD-1/VEGF-A antibodies for enhanced anti-tumor immunity Rui Zhang, Cheng Liu, Yuan Liu
- 2636 2636 靶向claudin 6的肿瘤微环境激活T细胞衔接器(TMEA-TCE)展示出疗效且不诱发细胞因子释放综合征 Tumor microenvironment-activated T-cell engager (TMEA-TCE) targeting claudin 6 demonstrates efficacy without inducing cytokine release syndrome Chengli Ding, Cheng Liu, Yuan Liu
-
-
-
- 2640 2640 XmAb808,一种B7H3靶向的CD28双特异性抗体,共刺激T细胞,增强临床活性CD3 T细胞衔接器的抗肿瘤活性 XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells enhancing the anti-tumor activity of clinically active CD3 T cell engagers Michael Hedvat, Veronica Zeng, Mayra Montes-Camacho, Charles G. Bakhit, Alex K. Lam, Lizett E. Scott, Jessica Reyes, Heather P. Jimenez, Rosio Padilla, Scott Taylor, Jose Serrato Bucio, Matthew A. Dragovich, Sung-Hyung Lee, Katrina Bykova, Yoon K. Kim, Suzanne Schubbert, Christine Bonzon, Seung Y. Chu, Gregory L. Moore, F. Rena Bahjat, John R. Desjarlais
- 2642 2642 泛癌种GlyTR1 CAR T细胞具有对beta1,6GlcNAc分支N-聚糖的"魔术贴样"密度依赖性靶向 Pan-cancer GlyTR1 CAR T cells with ‘velcro-like' density-dependent targeting of beta1,6GlcNAc-branched N-glycans Paresh Kumar Purohit, Raymond W. Zhou, Michael Demetriou
- 2643 2643 癌症患者中非单链CD3导向疗法引起细胞因子释放综合征的临床预测因素 Clinical predictors of cytokine release syndrome in non-single chain CD3 directed therapies among cancer patients Harshit Khosla, Brian Dinh, Rodney Hunter, Neha Maithel, Natalie Rafaeli, Sara Taveras, Joan Marie C Bull, Syed H. Jafri, Adan Rios
-
-
